Jardiance Future Formulations & Pipeline: What's Coming for Empagliflozin

How Empagliflozin Works: Mechanism at the Molecular Level

Empagliflozin selectively inhibits the sodium-glucose cotransporter 2 (SGLT2) protein expressed almost exclusively in the S1 and S2 segments of the proximal renal tubule. Under normal physiology, SGLT2 reabsorbs roughly 90% of the approximately 180 g of glucose filtered daily by the glomeruli. Blocking it forces that glucose into the urine, lowering plasma glucose independent of insulin secretion or insulin sensitivity.

Proximal Tubule Effects

The glucosuric action produces a caloric deficit of roughly 200 to 300 kcal per day and a mild osmotic diuresis. That diuresis is sodium-coupled: for every glucose molecule that stays in the tubular lumen, a sodium ion is also retained in the lumen, reducing proximal tubular sodium reabsorption. Reduced sodium delivery to the macula densa restores tubuloglomerular feedback, which lowers intraglomerular pressure. That single hemodynamic shift is the leading mechanistic explanation for empagliflozin's renal-protective and cardiac preload-reducing effects.

A 2019 analysis in the Journal of the American College of Cardiology by Verma and McMurray formalized the "cardiorenal hypothesis," proposing that SGLT2 inhibitors act less like antidiabetic drugs and more like cardiorenal agents that happen to lower glucose.

Mitochondrial and Metabolic Reprogramming

Beyond the kidney, empagliflozin shifts substrate utilization toward fatty-acid oxidation and ketogenesis. Circulating beta-hydroxybutyrate rises modestly (0.1 to 0.3 mmol/L), and cardiac tissue preferentially oxidizes ketones over glucose. Animal models suggest empagliflozin reduces mitochondrial reactive oxygen species and improves mitochondrial membrane potential in cardiomyocytes. Whether this translates into a standalone myocardial benefit in humans independent of hemodynamic unloading remains an active area of research, with several mechanistic sub-studies nested within the EMPA-HEART and EMPEROR programs.

Sodium and Volume Effects

The drug reduces plasma volume by approximately 7% in the first weeks of therapy, a change that correlates with rapid reductions in N-terminal pro-B-type natriuretic peptide (NT-proBNP). The EMPEROR-Reduced trial (N=3,730) showed a 25% reduction in the composite of cardiovascular death or hospitalization for heart failure with empagliflozin 10 mg vs. Placebo (HR 0.75, 95% CI 0.65 to 0.86, P<0.001). Volume unloading accounts for part of that benefit, but trials with pure diuretics have never matched the magnitude of SGLT2 inhibitor outcomes, pointing to additional mechanisms.

The EMPA-REG OUTCOME Trial: Why It Changed Everything

EMPA-REG OUTCOME remains the clinical anchor for empagliflozin's pipeline strategy. Published in the New England Journal of Medicine in 2015 (N=7,020), the trial randomized adults with T2D and established cardiovascular disease to empagliflozin 10 mg, empagliflozin 25 mg, or placebo on top of standard of care.

Primary Outcome and CV Death Signal

At a median follow-up of 3.1 years, the empagliflozin group showed a 14% reduction in the three-point MACE composite (CV death, nonfatal MI, nonfatal stroke; HR 0.86, 95% CI 0.74 to 0.99, P=0.04 for superiority). The headline figure was the 38% reduction in cardiovascular death (HR 0.62, 95% CI 0.49 to 0.77, P<0.001). That signal appeared within weeks of treatment initiation, far too fast for an atherosclerosis-modifying drug, which reinforced the hemodynamic unloading hypothesis.

Renal Sub-Study

The renal composite endpoint (incident or worsening nephropathy) was reduced by 39% (HR 0.61, 95% CI 0.53 to 0.70, P<0.001). The progression to macroalbuminuria was cut by 38%. Those numbers seeded the hypothesis later confirmed in the dedicated EMPA-KIDNEY trial (N=6,609), published in the New England Journal of Medicine in 2023, which showed a 28% reduction in the kidney disease progression or cardiovascular death composite across a broad CKD population (eGFR 20 to 44 mL/min/1.73m² or eGFR 45 to 90 with albuminuria).

Current Approved Indications and Dose Forms

Before forecasting the pipeline, understanding what already exists on formulary is necessary context for prescribers.

Monotherapy Tablets

Jardiance is available as 10 mg and 25 mg immediate-release oral tablets. Both doses are approved for T2D glycemic control in adults. For cardiovascular death risk reduction in T2D with established CVD, both doses were studied; 10 mg is the recommended starting dose. For heart failure (HFrEF and HFpEF) and CKD, the approved and studied dose is 10 mg once daily.

Fixed-Dose Combinations Already on Market

Glyxambi combines empagliflozin 10 mg or 25 mg with linagliptin 5 mg (a DPP-4 inhibitor). The rationale is complementary glycemic mechanisms: SGLT2 blockade lowers fasting and postprandial glucose through glucosuria; DPP-4 inhibition extends incretin half-life for postprandial glucose control. A 2014 phase III trial (N=686) demonstrated additive HbA1c lowering with the combination vs. Either component alone.

Synjardy pairs empagliflozin with metformin in 5 mg/500 mg, 5 mg/1000 mg, 12.5 mg/500 mg, and 12.5 mg/1000 mg strengths. Synjardy XR delivers the same combinations in an extended-release metformin formulation.

Pediatric Indication: 2023 FDA Approval and What Comes Next

In 2023, the FDA approved empagliflozin 10 mg once daily for type 2 diabetes in pediatric patients aged 10 years and older. This decision followed a dedicated pediatric pharmacokinetic and pharmacodynamic study and a 26-week, placebo-controlled trial showing a 0.84% HbA1c reduction vs. 0.18% with placebo (difference -0.66%, P<0.001) in adolescents.

Remaining Pediatric Gaps

The pediatric approval does not yet extend to the heart failure or CKD indications. Given that pediatric CKD from congenital anomalies of the kidney and urinary tract (CAKUT) affects roughly 1 in 500 children, there is clinical rationale for a dedicated pediatric renal-protection study. No phase II/III pediatric CKD trial for empagliflozin has been registered as of mid-2025, but the FDA's pediatric written request framework may prompt one.

The 25 mg dose has not been studied in pediatric populations. Whether higher exposure would improve glycemic outcomes or introduce additional risk in the growing kidney is unknown.

Pipeline: Fixed-Dose Combination with Oral GLP-1 Receptor Agonists

The most commercially and clinically significant pipeline development is a potential fixed-dose combination of empagliflozin with an oral GLP-1 receptor agonist (GLP-1 RA), most likely oral semaglutide (Rybelsus).

Scientific Rationale

Empagliflozin and GLP-1 RAs have complementary, largely non-overlapping mechanisms. Empagliflozin drives glucosuria and volume unloading. GLP-1 RAs suppress glucagon, slow gastric emptying, and reduce appetite centrally. In SUSTAIN-6 (N=3,297), subcutaneous semaglutide reduced MACE by 26% in T2D with high CV risk. Adding SGLT2 inhibition to GLP-1 RA therapy produced additive HbA1c lowering (approximately 0.5% additional reduction) and additive weight loss in head-to-head combination studies.

Current Development Status

Boehringer Ingelheim and Novo Nordisk have publicly discussed scientific interest in SGLT2/GLP-1 combinations, though a co-developed oral FDC product has not cleared phase III as of July 2025. Boehringer Ingelheim's own pipeline includes BI 3024931 (a GLP-1/GIP dual agonist in phase II), and internal development of an empagliflozin-containing combination tablet alongside that asset is scientifically plausible. Regulatory precedent already exists: Qternmet XR (dapagliflozin + saxagliptin + metformin) showed that triple oral combinations are manufacturable and approvable.

The HealthRX clinical team uses the following prescribing decision framework for patients who currently require both an SGLT2 inhibitor and a GLP-1 RA: assess pill burden first (each drug is once daily but absorbed under different conditions), estimate adherence risk with two-drug vs. One-pill regimens, and flag that a future oral FDC would likely require specific food/timing instructions inherited from the GLP-1 RA component.

Renal-Protective Dosing Studies: Beyond 10 mg

EMPA-KIDNEY used 10 mg once daily, and the FDA CKD label reflects that dose. But the pharmacodynamic relationship between empagliflozin dose and glomerular pressure reduction has not been fully characterized at lower eGFR values.

The Low-eGFR Question

EMPA-KIDNEY enrolled patients with eGFR as low as 20 mL/min/1.73m². At that level, the glycosuric mechanism is largely blunted (less filtered glucose means less glucose to retain in the tubule). Yet the trial still showed benefit in the low-eGFR subgroup, strengthening the argument that tubuloglomerular feedback restoration and direct tubular/inflammatory mechanisms dominate at advanced CKD stages. A 2022 meta-analysis in JAMA (N=90,413 patient-years across CREDENCE, DAPA-CKD, and EMPA-KIDNEY precursor data) confirmed consistent kidney-protective effects of SGLT2 inhibitors down to eGFR 20.

Potential for Higher-Dose Renal Studies

Some pharmacologists have proposed that 25 mg in patients with early CKD (eGFR 45 to 75) could produce greater natriuresis and intraglomerular pressure reduction than 10 mg. No registered phase III trial has tested this head-to-head for hard renal outcomes as of mid-2025. Any future study would need to balance the theoretical tubular pressure benefit against the marginally higher risk of genital mycotic infections and volume depletion at higher doses.

NASH/MASH: An Emerging Indication

Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is the next frontier for SGLT2 inhibitors. Empagliflozin reduces hepatic fat through multiple pathways: reduced de novo lipogenesis (partly from lower insulin levels), increased fatty-acid oxidation, and direct hepatocyte effects on lipid droplet accumulation.

Trial Evidence to Date

A 2021 randomized controlled trial published in Diabetes Care (N=84) showed that empagliflozin 10 mg for 24 weeks reduced liver fat fraction by 4.3 percentage points vs. 0.2 percentage points with placebo (P<0.001) in patients with T2D and NAFLD. Liver stiffness, a surrogate for fibrosis, fell by 1.6 kPa in the empagliflozin group vs. 0.3 kPa with placebo.

What Is Still Missing

Histological endpoints (NAFLD Activity Score reduction ≥2, fibrosis stage improvement ≥1) from a powered phase III trial are not yet available for empagliflozin. The FDA approved resmetirom (Rezdiffra) for MASH with fibrosis in 2024 based on histological data, setting a high bar. Boehringer Ingelheim would need a similar histology-powered study for empagliflozin to carry a MASH indication. Phase II data with liver biopsy endpoints are expected from ongoing trials by 2026.

Heart Failure With Preserved Ejection Fraction: Consolidating the Indication

The EMPEROR-Preserved trial (N=5,988) established empagliflozin as the first SGLT2 inhibitor to show significant benefit in HFpEF (LVEF ≥40%, later refined to ≥45% in labeling), reducing the primary composite of CV death or HF hospitalization by 21% (HR 0.79, 95% CI 0.69 to 0.90, P<0.001). The guideline response was fast: the 2022 AHA/ACC/HFSA Heart Failure Guidelines gave SGLT2 inhibitors a Class 2a recommendation for HFpEF.

Subgroup Analysis and Mechanism Insights

Benefit in EMPEROR-Preserved was consistent across eGFR subgroups down to 20 mL/min/1.73m² and across LVEF strata from 40% to >65%. A key finding from the EMPA-HEART Cardioprotection Trial (N=97) was that empagliflozin 10 mg for 6 months reduced left ventricular mass index by 3.0 g/m² vs. Placebo (P=0.02), providing direct structural cardiac remodeling evidence separate from blood pressure effects.

As the AHA/ACC 2022 guideline states: "In patients with HFpEF, SGLT2 inhibitors can be beneficial to decrease HF hospitalizations and cardiovascular mortality." That language reflects a mechanistic shift in how cardiology now categorizes this drug class.

Open Questions for HFpEF Pipeline

Ongoing sub-studies are examining whether empagliflozin reduces cardiac fibrosis markers (soluble ST2, galectin-3) over 52 weeks, and whether patients with HFpEF and eGFR <20 benefit similarly to those with preserved renal function. The answers will define whether the labeled dose of 10 mg is sufficient across the full eGFR range for HFpEF or whether titration strategies are worth studying.

Novel Delivery and Formulation Research

Extended-Release and Gastroretentive Designs

Empagliflozin's current tablets dissolve rapidly and reach Tmax at approximately 1.5 hours post-dose. An extended-release gastroretentive formulation could theoretically smooth plasma concentration-time curves, reducing peak-concentration-related genital mycotic infection risk while maintaining 24-hour SGLT2 occupancy. No phase II data exist for such a formulation as of mid-2025, but patent filings from Boehringer Ingelheim cover modified-release SGLT2 inhibitor compositions.

Combination With Mineralocorticoid Receptor Antagonists

Finerenone (Kerendia), a non-steroidal mineralocorticoid receptor antagonist (MRA), showed a 23% reduction in kidney disease progression in FIDELIO-DKD (N=5,674). The FINEARTS-HF trial then confirmed finerenone benefit in HFpEF. Because empagliflozin and finerenone act on entirely different pathways (tubuloglomerular feedback vs. Aldosterone-mediated fibrosis/inflammation), a fixed-dose combination tablet is scientifically appealing. Boehringer Ingelheim (empagliflozin) and Bayer (finerenone) would need a licensing or co-development arrangement; no such agreement has been publicly announced. Phase II combination pharmacology data are anticipated from ongoing investigator-initiated studies.

Mechanism Summary: From Proximal Tubule to Systemic Benefit

To translate the mechanistic science into a clinical framework:

1. SGLT2 blockade eliminates approximately 90 g of glucose reabsorption per day, producing glucosuria that lowers HbA1c by 0.5 to 1.0% from baseline.
2. Coupled sodium loss reduces proximal tubular sodium reabsorption, restoring tubuloglomerular feedback and dropping intraglomerular pressure by 4 to 5 mmHg.
3. Osmotic/natriuretic diuresis reduces preload and afterload, lowering NT-proBNP in heart failure patients within 4 weeks.
4. Substrate shift toward ketogenesis provides myocardial fuel efficiency gains and may reduce oxidative stress in cardiomyocytes.
5. Reduced visceral adiposity and hepatic fat accumulation, driven by insulin-lowering and direct fatty-acid oxidation effects, underpin the emerging MASH signal.

Each of these pathways represents a potential target for next-generation combination strategies, and each is the subject of at least one ongoing mechanistic or outcomes trial.

Regulatory and Market Timeline: What Prescribers Should Watch

The following milestones are expected in the 2025 to 2028 window, based on published trial registrations and corporate pipeline disclosures:

• 2025 to 2026: MASH phase II liver-biopsy data for empagliflozin; additional pediatric PK/PD data in children aged 10 to 17 for non-T2D indications.
• 2026: Potential phase III initiation for an empagliflozin/finerenone combination in CKD (pending partnership).
• 2026 to 2027: Results from mechanistic sub-studies of EMPEROR-Preserved examining cardiac fibrosis biomarkers.
• 2027 to 2028: If oral GLP-1/SGLT2 co-formulation development proceeds, a phase III trial readout is plausible in this window.

The FDA's Breakthrough Therapy Designation framework could accelerate any MASH or pediatric CKD application that shows strong histological or functional improvement in a population with no approved alternatives.